Recent advances in carcinoid pathogenesis, diagnosis and management

Surgical Oncology

Volumn 9, Issue 4, 2000, Pages 173-179

  Ganim, Rose B ^a,b,c,d   Norton, Jeffrey A ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d San Francisco Hospital   (United States)

Author keywords

Carcinoid; Chromogranin A; Positron emission tomography; Serotonin receptor; Somatostatin analogue; Somatostatin receptor scintigraphy

Indexed keywords

ANGIOPEPTIN; ANOREXIGENIC AGENT; BIOLOGICAL MARKER; CYPROHEPTADINE; FENFLURAMINE; KETANSERIN; METHYSERGIDE; OCTREOTIDE; PHENTERMINE; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SOMATOSTATIN DERIVATIVE; TUMOR MARKER;

AGGRESSIVENESS; CARCINOID SYNDROME; CHOLELITHIASIS; CLINICAL TRIAL; DIAGNOSTIC VALUE; DIARRHEA; HEART DISEASE; HUMAN; HYPERGLYCEMIA; METASTASIS; MOLECULAR BIOLOGY; NAUSEA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; STEATORRHEA; SYMPTOMATOLOGY; TACHYPHYLAXIS; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR SCINTISCANNING; VOMITING;

EID: 0034434765     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-7404(01)00007-X     Document Type: Article

References (59)

1. Gastric carcinoid tumors: The biology and therapy of an enigmatic and controversial lesion
2. Uaber die "kleinen dunndarm carcinome"
3. The epidemiology of carcinoid tumours in England and Scotland
4. The classification of carcinoid tumors
5. Thymic carcinoid in association with MEN syndromes
6. Activation of the nuclear oncogenes N-myc and c-jun in carcinoid tumors of transgenic mice carrying the human genome adenovirus type 12 E1 region gene
7. Expression and co-expression of cellular oncogenes in the course of tumor progression in the course of neuroendocrine lung tumors
8. New molecular aspects for the diagnosis and treatment of neuroendocrine gastroenteropancreatic tumors
9. Genome-wide search for loss of heterozygosity in transgenic mouse tumors reveals candidate tumor supressor genes on chromosomes 9 and 16
10. Infrequent mutation in the p53 gene in pulmonary carcinoid tumors
11. Overexpression of the tumor suppressor gene p53 is not implicated in neuroendocrine tumor carcinogenesis
12. Absence of overexpression of p53 protein by intestinal carcinoid tumors
13. The spectrum of neuroendocrine differentiation among gastrointestinal carcinoids: Importance of histologic grading, MIB-1, p53, and bcl-2 immunoreactivity
14. A typical bronchopulmonary carcinoids show a tendency toward increased apoptotic and proliferative activity
15. Carcinoid heart disease: Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization, echocardiography
16. Expression of 5-hydroxytryptamine receptor subtype messenger RNA in interstitial cells from human heart valves
17. Mitogenic and secretory responses of human valve interstitial cells to vasoactive agents
18. Valvular heart disease associated with fenfluramine-phentermine
19. 2B receptors in the cardiopathy associated with fenfluramine
20. Signaling from G-protein-coupled receptors to mitogen-activated protein [MAP]-kinase cascades
21. The role of neuropeptides and seretonin in the diagnosis of carcinoid tumors
22. Measurements of chromagranin A, chromagranin B (secretogranin I), chromagranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours
23. Secretion of a chromaffin granule protein, chromogranin from the adrenal gland after splanchnic stimulation
24. Tumor markers in neuroendocrine tumors
25. Carcinoid tumors. Analysis of prognostic factors and survival in 301 patients from a referral center
26. Chromogranin A, neuron-specific enolase, carcinoembryonic antigen and hydroxyindole acetic acid evaluation in patients with neuroendocrimne tumors
27. Usefulness of chromogranin A as a marker for detection of relapses of carcinoid tumors
28. Carcinoid tumor: Images, procedures and interventional radiology
29. Value of somatostatin receptor scintigraphy for preoperative localization of carcinoids
30. Bronchial carcinoid tumors: Radiologic observations in 49 cases
31. Primary gastric carcinoid tumors: A view on management
32. Carcinoid tumors of the gastrointestinal tract: Presentation, management and prognosis
33. Sonographic appearance of small bowel carcinoid tumor
34. Percutaneous ultrasonography-guided cutting biopsy from liver metastases of endocrine gastrointestinal tumors
35. Endoscopic assessment of invasion of colorectal tumors with a new high frequency ultrasound probe
36. Carcinoid tumors of the gastrointestinal tract: Evaluation with endoscopic ultrasonography
37. Surgical treatment of mid-gut carcinoid tumors
38. Expression of somatostatin receptors in normal, inflammed, and neoplastic human gastrointestinal tissue
39. Use of an isotopic somatostatin probe to image gut endocrine tumors
40. Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: Bone scintigraphy compared with somatostatin receptor scintigraphy
41. Evaluation of primary pulmonary carcinoid tumors using FDC PET
42. Use of PET in neuroendocrine tumors: In vivo applications and in vitro studies
43. Positron emission tomography with 5-hydroxytryptophan in neuroendocrine tumors
44. 11C] 5-hydroxy-L-tryptophan uptake and decarboxylation in carcinoid tumors by specific positioning labeling in positron emission tomography
45. Neuroendocrine gastrointestinal tumors - A condensed overview of diagnosis and, treatment
46. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: Future outlook
47. Efficacy and safety of prolonged-release Lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms
48. Treatment of carcinoid syndrome: A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, tolerance
49. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR
50. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome
51. Carcinoid tumors
52. Serotonin, catecholamines, histamine, and their metabolites in urine, platelets, and tumor tissue of patients with carcinoid tumors
53. Neuroendocrine tumors of the pancreas and gastrotintestinal tract carcinoid disease
54. Midgut carcinoid tumors
55. 1]-octreotide
56. Somatostatin receptor scintigraphy in gastroenteropancreatic tumors. An over view of European results
57. Somatostatin receptor scintigraphy in the management of gastroenteropancreatic tumors
58. Value of somatostatin receptor scintigraphy for preoperative localization of carcinoids
59. Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors